Cytiva Expands Operations in India with New Pune Manufacturing Facility & Training Centre

US-based Cytiva, a global life sciences company, has unveiled its latest manufacturing facility and Experience Centre in Pune, India. 

This move aims to strengthen Cytiva's manufacturing capabilities in the region while stimulating the development of innovative therapeutic solutions.

Cytiva's newly established manufacturing facility in Pune will play a key role in doubling its Indian manufacturing capacity. It will primarily focus on producing essential bioprocessing equipment, such as tangential flow systems, virus filtration tools, and inactivation systems. 

The expansion will substantially contribute to meeting the growing demand for biologic medicines in healthcare.

Furthermore, the Experience Centre accompanying the manufacturing facility will be a hub for immersive training programs. These programs will cover various topics, including upstream and downstream technologies, digital solutions, and automation software. The goal is to provide critical training that accelerates the development of novel therapeutics and enhances the skills of professionals in the life sciences industry.

Commenting on the importance of this expansion, Rajan Sankaran, said, "Strengthening our manufacturing presence in India is vital to Cytiva's operations in Asia-Pacific and long-term growth strategy. We also have a pivotal role in developing and nurturing the talent required to meet the demand for biologic medicines."

The new facility includes a Fast Trak Centre and a dedicated research and development center spanning various sectors, including bioprocessing, discovery, medical, and genomic medicine. 

Established in 2016 in Massachusetts, USA, Cytiva, now with the life sciences business from Pall Corporation, stands as a global leader in life sciences. 

By combining specialised technical knowledge and an extensive array of tools and technologies, they facilitate the creation, production, and distribution of novel medicines for patients.

Cytiva's 2023 Global Biopharma Resilience Index highlights an intriguing statistic - 65% of biopharma executives in India anticipate an increase in biologics manufacturing over the next three years. 

This figure surpasses the global average by 15%. Additionally, 46% of Indian biopharma executives prioritise onshoring drug manufacturing or increasing domestic sourcing in the coming year to bolster supply chain resilience.